Floatz logo

Entrectinib

Haematological Malignancy

Cancer Research UKSmall moleculePhase 2/3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

136 Active assets in the Haematological Malignancy cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Entrectinib is also rated in:

Anatomic Stage IV Breast Cancer AJCC v8Dormant
B
Indicative ·
62 / 100
View asset →
sarcomaDormant
B
Indicative ·
60 / 100
View asset →
neoplasmDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →